ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: FR-PO1004

A Mouse Model for "Definitive" Polyomavirus Nephropathy with Lytic Viral Replication

Session Information

  • Transplantation: Basic
    October 25, 2024 | Location: Exhibit Hall, Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Transplantation

  • 2101 Transplantation: Basic

Authors

  • Nickeleit, Volker, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, United States
  • Butcher, Dalton R., The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, United States
  • Thompson, Bawana D., The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, United States
  • Singh, Harsharan Kaur, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, United States
Background

A mouse model for polyomavirus nephropathy (PyVN) with lytic viral replication has not been described. Studies of PyVN based on observations in kidney transplants have limitations due to concurrent alloimmune injury.

Aim: Characterization of a model of PyVN in native mouse kidneys.

Methods

Black Swiss mice i.p. injected with murine strain A2 PyV (MUPyV; 1x107 PFU) reliably developed PyVN. Animals (n>100) were sacrificed at different intervals (end point 54 weeks). Testing performed: light microscopy (LM), electron microscopy (EM), immunohistochemistry (IHC), plasma anti-MUPyV antibody titers, PCR (kidney, plasma, urine), genetics on MUPyV stability.

Results

PyVN with lytic replication occurred in all animals 2 weeks post infection. It peaked at 2-5 weeks (Fig: IHC for PyV-Capsid Protein-1; viral replication in 6.1% (median) of cortical tubules), subsequently decreased (weeks 6-30) and ultimately cleared by LM/IHC in all animals (weeks 47-54). At the end of follow-up subclinical infections (positivity in kidney/plasma/urine only by PCR; no changes by LM/IHC) were only seen in 15% of mice. Viral progeny were detected in the cytoplasm and nuclei of tubular and some mesenchymal cells by EM. Viral injury dominated in distal tubules and cortical collecting ducts. It was associated with inflammation rich in CD3+and CD4+ cells (75%) with fewer admixed myofibroblasts and F4/80+ histiocytes (20%-40%). Fibrosis did not occurr. During PyVN, MUPyV remained genetically stable. In week 3-5 post infection animals mounted a transient IgM reponse that disappeared during week 6-30 when IgG titers peaked. At the end of follow-up IgM was no longer detected while IgG titers were low positive in 92% of animals.

Conclusion

Our PyVN mouse model in native kidneys is robust. Morphologic, molecular, genetic, and immunologic changes mimick human disease whereas scarring is absent. The model is well suited for targeted studies/ interventional drug trials.

Funding

  • Clinical Revenue Support